20 mayo 2016

Myeloma Multiple : Adding Liposomal Doxorubicin to Bortezomib Fails to Improve Survival .

Jason Hoffman, PharmD, RPh /// May 19, 2016 .

The addition of pegylated liposomal doxorubicin to bortezomib did not improve overall in relapsed/refractory multiple myeloma.
The addition of pegylated liposomal doxorubicin to bortezomib did not improve overall in relapsed/refractory multiple myeloma.

...